BridgeBio Pharma, Inc.
BBIO
$32.19
-$0.82-2.48%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2,285.27% | 2,209.77% | 3,761.22% | 181.05% | -88.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2,285.27% | 2,209.77% | 3,761.22% | 181.05% | -88.02% |
| Cost of Revenue | 58.54% | -4.13% | -9.26% | -12.57% | -28.77% |
| Gross Profit | 3,079.58% | 3,006.49% | 7,031.69% | 188.11% | -90.76% |
| SG&A Expenses | 91.87% | 79.23% | 60.19% | 41.89% | 5.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.30% | 35.52% | 39.76% | 33.50% | 11.47% |
| Operating Income | 3.68% | 2.14% | 1.57% | -7.43% | -27.97% |
| Income Before Tax | 17.00% | 28.42% | 21.00% | -28.31% | -34.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 16.82% | 28.42% | 21.00% | -28.31% | -34.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.52% | -31.54% | -31.32% | 656.92% | 189.68% |
| Net Income | 16.70% | 28.37% | 20.80% | -26.67% | -33.67% |
| EBIT | 3.68% | 2.14% | 1.57% | -7.43% | -27.97% |
| EBITDA | 3.65% | 2.11% | 1.55% | -7.55% | -28.44% |
| EPS Basic | 27.90% | 38.26% | 29.73% | -13.87% | -21.03% |
| Normalized Basic EPS | 9.58% | 12.76% | 12.41% | -16.73% | -34.82% |
| EPS Diluted | 27.90% | 38.26% | 29.73% | -13.87% | -21.03% |
| Normalized Diluted EPS | 9.58% | 12.76% | 12.41% | -16.73% | -34.82% |
| Average Basic Shares Outstanding | 14.33% | 16.53% | 15.33% | 13.48% | 10.36% |
| Average Diluted Shares Outstanding | 14.33% | 16.53% | 15.33% | 13.48% | 10.36% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
